Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue: +3,749.2%
EPS: +549.1%
Free cash flow: +839.7%

Quarter to June 2026, against a year earlier

131.78 3.48 −2.57%

Follow PTGX

Alert me

Market cap: $8.8B
P/E: 111×
Fwd P/E: 31.2×
Dividend yield: —
F-score: 4/9
Altman Z: 61.55
Beneish M: −7.18
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Protagonist Therapeutics, Inc. (PTGX) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Protagonist Therapeutics, Inc. (PTGX) trades at a P/S ratio of 31.7×. Over the past ten years it has ranged from 0.0× (December 2019) to 1,034× (February 2020); the current reading is higher than 69% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PTGX/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Protagonist Therapeutics, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PTGX/metrics/ps-ratio">Protagonist Therapeutics, Inc. (PTGX) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	121×	2,105.80%
FY2024	5.5×	(81.28%)
FY2023	29.2×	151.46%
FY2022	11.6×	(79.93%)
FY2021	57.9×	139.08%
FY2020	24.2×	(96.93%)
FY2019	790×	16,137.01%
FY2018	4.9×	—
FY2017	0.0×	—

Period	P/S ratio	Change
Jun 2026	28.7×	(69.06%)
Mar 2026	92.6×	(23.24%)
Dec 2025	121×	495.91%
Sep 2025	20.2×	20.67%
26 more quarters	Free account

Against its own ten years

Low 0.0× High 1,034×

Ten-year median 15.6×

Current reading's percentile 61

Company	P/S ratio
CAI Caris Life Sciences,�Inc. compare	7.1×
MDGL Madrigal Pharmaceuticals, Inc. compare	8.2×
TGTX TG Therapeutics, Inc. compare	10.3×
TWST Twist Bioscience Corporation compare	17.6×
KRYS Krystal Biotech, Inc. compare	18.9×
PTGX Protagonist Therapeutics, Inc.	31.7×
IBRX ImmunityBio, Inc. compare	51.0×
CYTK Cytokinetics, Incorporated compare	64.4×
SYRE Spyre Therapeutics, Inc. compare	8,160×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Protagonist Therapeutics, Inc. (PTGX) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on PTGX

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on PTGX

Stockrow Weekly